Interferon-alpha induced transient thyroid dysfunction in hepatitis C
Rev Esp Enferm Dig. 2002 Mar;94(3):159-63.
[Article in
English,
Spanish]
Affiliation
- 1 Gastroenterology Unit, Hospital Clínico San Carlos, Madrid, Spain. sfernandezd@medynet.com
Abstract
We report the case of thyroid dysfunction that developed in a 36-year-old female patient who required combination therapy with interferon and ribavirine for chronic hepatitis C. Firstly, she suffered a hyperthyroidism followed by a hypothyroidism stage requiring thyroxine replacement therapy. Nevertheless, combination treatment was not discontinued, reaching a sustained biochemical and virological response. The pathogenesis of autoimmune diseases in patients with Hepatitis C virus infection and interferon therapy is not clear, but usually these disorders are reversible and only require supervision and treatment if clinical or laboratory abnormalities are present.
MeSH terms
-
Antiviral Agents / adverse effects*
-
Antiviral Agents / therapeutic use
-
Female
-
Hepatitis C / complications*
-
Hepatitis C / drug therapy
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / adverse effects*
-
Interferon-alpha / therapeutic use
-
Middle Aged
-
Recombinant Proteins
-
Thyroid Diseases / chemically induced*
-
Thyroid Diseases / complications
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins